NCT01032148View on ClinicalTrials.gov

Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

PHASE1TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Hodgkin's LymphomaNon-Hodgkin's Lymphoma

Interventions

DRUG

LBH589

LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER